NEW YORK (GenomeWeb News) – Sengenics and Parkway Laboratory Services have entered into a partnership to offer genetics tests in Singapore, Sengenics said on Thursday.
The deal focuses on Sengenics' CardioSure heart disease test and Sequenom's MaterniT21 Plus non-invasive prenatal diagnostic test. The CardioSure test, Sengenics said, is based on a concept of "Asianized Diagnostics" to include disease biomarkers from Asian ethnic groups as well as those from Caucasian and African populations.
Meanwhile, Sengenics entered into a deal with Sequenom in the fall to offer MaterniT21 Plus in Singapore and Malaysia.
Starting May 1, the two tests will be made available through Parkway Lab. Financial details of the deal with Sengenics were not disclosed.
Based in Kuala Lumpur, Malaysia, Sengenics provides genomics- and proteomics-based diagnostics. Earlier in the month it and CollabRx announced a deal to incorporate each other's products into molecular tests and reports aimed at cancer.
Parkway Lab is part of the Parkway Pantai group and provides laboratory services in Singapore.